Newsletter | June 22, 2022

06.22.22 -- 2 Female Execs On Diversity & Inclusion

Featured Articles
Diversity & Inclusion Through The Eyes Of Two Female Pharma Executives

In the following, we present two first-hand accounts of what it has been like to be a woman working in the pharma industry for many years and what we can all do to overcome the industrywide challenge related to diversity and inclusion.

CoCrystal’s Co-CEOs

Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.

4 Steps To A More Resilient/Intelligent Supply Chain

As life sciences supply chains have become more global and complex, the ability to withstand and respond to expected disruptions and failures requires a level of visibility and agility that is simply not in place today.

Web-Exclusive Content
FDA Releases Guidance On Cybersecurity In Medical Devices

The digital revolution that resulted in the IoT, IoMT, SaMD, and connected devices comes with the possibility of cyberattacks. The FDA's latest efforts to enhance medical device cybersecurity include a new draft guidance (covered in this article) and bipartisan congressional support of the PATCH Act of 2022 (which will be covered in a future article).

Industry Insights
A Road Map For Early Development To Commercial Manufacturing

Learn how to avoid common pitfalls in the transfer and scale-up process using an integrated approach, with industry experts sharing key considerations when planning for scale-up of a development program.

Pharmaceutical Distribution: Right-Sizing The Channel Strategy For Maximum Impact

The goal is to create a nimble, data-driven infrastructure that can connect the therapy to the customer base more effectively, helping to speed therapy onboarding for patients while improving visibility.

Precise Medical Research Requires Precision Outsourcing

Biopharma companies often are unable to draw maximum value from their clinical research outsourcing (CRO) partners. In this e-book, find out four reasons why this occurs.

The Importance Of CMC Developability Assessments: A Conversation With AltruBio’s Dr. Gene Lee

Dr. Gene Lee, vice president of technical development at AltruBio, sat down to discuss getting the developability question right and why it’s important to understand your end game as early as discovery.

Digital Edition
June 2022 Digital Edition

Inside you will find more on:

  • Industry Research
  • Exclusive Executive Interviews
  • China Biopharma Update
  • Diversity & Inclusion Topics

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.